NVO announcements Novo Nordisk A/s announcements and dividends declared NYSE
Novo Nordisk A/s Complete list of announcements declared & dividend announcements by Novo Nordisk A/s NVO
Novo Nordisk A/s NVO listed on NYSE and deals in Health Care Major PharmaceuticalsAnnouncements and dividends declared by Novo Nordisk A/s NVO
Generic drug companies rework pricing to gain weight in India’s GLP-1 market as Novo Nordisk slashes Wegovy prices
Indian drugmakers are adjusting prices for weight-loss injections after Novo Nordisk cut prices for its drug Wegovy. This move is prompting generic companies to lower their expected launch prices. Novo Nordisk is also preparing to launch Ozempic in India s
Announcement as on 26 November 2025
Novo Nordisk's obesity drug shows weight loss of up to 14.5% in mid-stage study
Novo Nordisk said its new experimental obesity drug, amycretin, delivered up to 14.5% weight loss at 36 weeks in type 2 diabetes patients in a mid-stage trial. The drug was found to be safe with mostly mild gastrointestinal side effects, and the company pl
Announcement as on 25 November 2025
Novo Nordisk India prioritises patient outcomes; revenue growth follows naturally, says Shrotriya
Novo Nordisk India head Vikrant Shrotriya revealed a strategic 37% price cut for obesity drug Wegovy, aiming for wider accessibility. The company is preparing for semaglutide patent expiry next year by focusing on trust, quality, and education, mirroring
Announcement as on 19 November 2025
Patent expiry looms: Eli Lilly and Novo Nordisk strategise to defend their top obesity drugs in India
Eli Lilly and Novo Nordisk leaders share their India strategies for weight-loss drugs. They focus on pricing, market expansion and countering generics after semaglutide's patent ends. Both companies aim to increase patient access to their innovative thera
Announcement as on 18 November 2025
Novo Nordisk cuts weight-loss drug Wegovy's price by up to 33% in India, document shows
Novo and Lilly are locked in a race for dominance in India, a key battleground for weight-loss treatments in the booming global market, which analysts estimate could be worth 0 billion annually by the end of the decade. "This appears like prices have be
Announcement as on 11 November 2025
Announcements by Novo Nordisk A/s first page | Next page | Prev page |
NVO Novo Nordisk A/s current price & indicator signals
Recent prices of NVO Novo Nordisk A/s are as follows: Daily volume is divided by 10 day averaged volume
| Date | Close | Range | Change % | Volume |
| 15 Fri May 2026 | 44.74 | 44.25 to 45.50 | -2.31% | 0.94 times |
| 14 Thu May 2026 | 45.80 | 45.54 to 46.84 | -2.72% | 0.76 times |
| 13 Wed May 2026 | 47.08 | 46.65 to 47.21 | 0.17% | 0.57 times |
| 12 Tue May 2026 | 47.00 | 46.29 to 47.11 | 1.29% | 0.82 times |
| 11 Mon May 2026 | 46.40 | 46.27 to 47.79 | 0.72% | 1.03 times |
| 08 Fri May 2026 | 46.07 | 45.19 to 46.14 | 0.59% | 0.69 times |
| 07 Thu May 2026 | 45.80 | 45.75 to 47.08 | 0.11% | 0.97 times |
| 06 Wed May 2026 | 45.75 | 45.53 to 47.55 | -0.02% | 1.49 times |
| 06 Wed May 2026 | 45.76 | 45.53 to 47.55 | 1.94% | 1.78 times |
| 05 Tue May 2026 | 44.89 | 44.21 to 45.12 | 1.13% | 1.02 times |
| 04 Mon May 2026 | 44.39 | 43.39 to 45.02 | 1.16% | 0.86 times |
| 01 Fri May 2026 | 43.88 | 43.10 to 44.04 | 3.93% | 1.51 times |
Videos related to: NVO announcements Novo Nordisk A/s announcements and dividends declared NYSE
Hindi Video Correct Way Of Fundamental Analysis Using EPS And PE - MunafaSutra
Hindi Video What Is Needed To Succeed In Stock Markets
- NYSE Screeners
- NYSE Daily Screener
- NYSE Weekly Screener
- NYSE Monthly Screener
- Support & Resistance
- NYSE Shares Near Support
- NYSE Shares Near Resistance


